

Limitations of Contemporary Antidepressants: Tolerability

George I. Papakostas, M.D.

Antidepressant side effects are common and persistent. They can contribute to discomfort, distress, disability, morbidity, and mortality and can compromise the efficacy of treatments. Reducing the side effect burden, either by developing treatments that have a lower incidence of side effects or by using treatment strategies that alleviate side effects, would improve the standard of care for mood and anxiety disorders. In this article, the rates of common adverse events among the newer (posttricyclic era) antidepressants are compared with those among the selective serotonin reuptake inhibitors, the most popular, contemporary first-line treatments for depression.

(J Clin Psychiatry 2007;68[suppl 10]:11–17)

Side effects can occur at varying times during treatment of mood or anxiety disorders with antidepressants. When they appear early during treatment, side effects can contribute to additional patient discomfort and distress as well as compromise efficacy. Long-term side effects can result in discomfort and distress and delay the restoration of psychosocial functioning, as well as contribute to increased morbidity, mortality, and a loss of therapeutic gains.

ACUTE AND LONG-TERM SIDE EFFECTS

Side effects present during the acute phase of pharmacotherapy for depression are both common and persistent. Hu et al.¹ studied 401 patients with depression who were prescribed a selective serotonin reuptake inhibitor (SSRI). Following 75 to 105 days of treatment, 86% of patients reported 1 side effect or more, while 55% reported at least 1 side effect they considered bothersome. In addition, while most side effects first appeared during the initial 2 weeks of treatment, the majority of patients continued to experience the same side effect 75 to 105 days later.

In addition, discrepancies existed in the timing of certain side effects (e.g., acute versus long term), but not in others.¹ For instance, a high percentage of patients (82%) experienced nausea following 2 weeks of treatment, but by 3 months, only 32% of those patients continued to complain of nausea. In contrast, the percentage of patients who experienced weight gain increased over time (29% to 59%). However, insomnia, drowsiness, and sexual dysfunction began early and persisted (approximately 64% to 69%, 56% to 69%, and 62% to 83%, respectively).¹ Thus, even though antidepressant side effects have traditionally been divided into short-term and long-term categories, this division appears to be mostly artificial (Figure 1).

Side effects present during the acute phase of treatment of depression may add to patient suffering and distress, contribute to a delay in attaining an effective or optimal antidepressant dose, and contribute to poor or intermittent compliance or noncompliance altogether. Lin et al.² studied adherence to antidepressant therapy in a naturalistic sample of 155 patients starting a new prescription with a tricyclic antidepressant (TCA), trazodone, or fluoxetine. At 2 weeks, 20.6% of patients had discontinued treatment, and at 4 months, 51.2% had discontinued treatment. Side effects were cited as the reason for discontinuation by 62.2% of those who discontinued treatment within the first 30 days and by 66.7% of patients who discontinued treatment between days 31 and 90. Although this study found that the greatest drop in adherence occurred within the first 2 weeks of treatment, the majority of patients who discontinued treatment later did so because of intolerable side effects. These results challenge the traditional belief that, if patients endure side effects initially, then the rate of discontinuation due to side effects will decrease.

A variety of side effects may also occur during the long-term treatment of depression, which may contribute to distress, a delay or failure in restoring psychosocial


From the Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston.

This article was derived from the planning roundtable "The Role of Folate in Depression and Dementia," which was held January 18, 2007, in Philadelphia, Pa., and supported by an educational grant from PamLab, L.L.C.

Dr. Papakostas has served as a consultant for Aphios, Bristol-Myers Squibb, Evotec, GlaxoSmithKline, Inflabloc, Jazz, PamLab, Pfizer, and Wyeth; has received research support from Bristol-Myers Squibb, PamLab, and Pfizer; and has received honoraria from Evotec, GlaxoSmithKline, Inflabloc, Jazz, PamLab, Pfizer, and Titan.

Corresponding author and reprints: George I. Papakostas, M.D., Massachusetts General Hospital, 50 Staniford St., 4th Floor, Boston, MA 02114 (e-mail: gpapakostas@partners.org).

Figure 1. Short- and Long-Term Side Effects Associated With Antidepressant Medication



functioning (e.g., excessive daytime somnolence, fatigue, and cognitive side effects and their effects on work productivity), increased morbidity and mortality (e.g., obesity and vascular illness, lethargy and motor vehicle accidents, falls, and fractures), and a loss of therapeutic gains due to poor compliance, noncompliance, or a need to reduce the antidepressant dose.

RELATIVE PREVALENCE OF SIDE EFFECTS WITH VARIOUS ANTIDEPRESSANTS

In a study by Hu et al.,¹ patients were asked to rank which side effects they believed to be most bothersome. Sexual dysfunction was most frequently rated (16.7%), followed by drowsiness/fatigue (16.5%), weight gain (11.5%), and insomnia (11.2%). Nausea was also reported as bothersome by 5.7% of patients. The remainder of this article will focus on describing the relative prevalence of these 5 side effects among the newer (post-TCA era) antidepressants. When available, data from meta-analyses of randomized, controlled trials will be used as an estimate of the relative likelihood of developing a given side effect during treatment with various antidepressant agents. In the absence of data from meta-analyses, data from individual randomized, controlled trials will be presented instead. Since most antidepressant comparator trials involve the use of an SSRI in the post-TCA era, the prevalence of side effects during treatment with other newer antidepressants compared to the SSRIs will be related.

Nausea

The SSRIs appear to be associated with equivalent or higher rates of nausea when compared with most non-SSRI medications. Specifically, treatment with the SSRIs appears to result in higher rates of nausea than bupropion,³ moclobemide,⁴ reboxetine (G.I.P.; J. C. Nelson, M.D.; S. Kasper, M.D.; et al., manuscript submitted), and mirtazapine.⁵ However, comparative studies of SSRIs

and trazodone,⁶⁻⁹ nefazodone,¹⁰⁻¹⁴ and duloxetine¹⁵⁻²⁰ have found that nausea rates were roughly equivalent. Venlafaxine appears to have a higher incidence of nausea than SSRIs.²¹⁻²⁶ Finally, it is worth noting that nausea resulting from the use of either venlafaxine or paroxetine may be reduced by using controlled-release formulations rather than immediate-release formulations of these 2 agents (i.e., venlafaxine extended release and paroxetine controlled release).²⁶

Insomnia

Treatment with the SSRIs appears to result in higher rates of insomnia than mirtazapine,⁵ trazodone,^{6,7} and nefazodone.^{13,14} Equivalent rates of insomnia have been found among the SSRIs and bupropion,³ moclobemide,⁴ duloxetine,¹⁶⁻¹⁹ and venlafaxine.^{21-25,27-39} Finally, reboxetine was found to have a higher rate of insomnia compared with SSRIs (G.I.P.; J. C. Nelson, M.D.; S. Kasper, M.D.; et al., manuscript submitted and reference 40).


Somnolence and Fatigue

Somnolence and fatigue are also common side effects associated with antidepressant use. Treatment with SSRIs has been found to result in a higher rate of somnolence and fatigue than bupropion^{3,41} and reboxetine (G.I.P.; J. C. Nelson, M.D.; S. Kasper, M.D.; et al., manuscript submitted). Moclobemide,⁴ nefazodone,¹⁰⁻¹³ venlafaxine,^{21-25,27-30,32,33,36,37} and duloxetine¹⁵⁻¹⁹ were all found to have rates of somnolence and fatigue equivalent to those of the SSRIs. Finally, treatment with mirtazapine⁵ and trazodone⁶ appeared to result in greater rates of somnolence and fatigue than SSRI treatment.

Sexual Dysfunction

Antidepressant treatment may also result in a variety of sexual side effects ranging from decreased libido, arousal dysfunction (i.e., inhibited sexual excitement, diminished genital sensation, erectile dysfunction, and failure to achieve or maintain vaginal lubrication), and orgasm disorders (i.e., delayed orgasm and partial or complete anorgasmia).⁴² Sexual side effects are notoriously underreported by patients, and physicians must often ask about such bothersome adverse events. Montejo-Gonzalez et al.,⁴³ for instance, studied 344 patients prescribed fluoxetine, fluvoxamine, paroxetine, and sertraline and found that sexual dysfunction was reported by 58% of patients when physicians *directly inquired* about such side effects, compared with a mere 14% of patients who *spontaneously reported* sexual side effects.

Clayton et al.⁴⁴ investigated the prevalence of sexual dysfunction with a number of newer agents, including the SSRIs, bupropion, mirtazapine, nefazodone, and venlafaxine, prescribed to more than 6000 patients. The treatments with the lowest rate of sexual dysfunction were bupropion immediate release (22% to 25%) and nefazodone (28%).

Figure 2. Weight Gain Following 1 Year of Treatment (95% CI)^a

^aData on file, GlaxoSmithKline, Brentford, Middlesex, U.K. Proportion of patients with weight gain and 95% CIs depicted in the General Electric Medical Records Database.

The prevalence of sexual dysfunction following treatment with the remaining agents ranged from 36% to 43%.

Randomized controlled trials that employed a scale to specifically measure sexual dysfunction reported that SSRI treatment resulted in significantly higher rates of sexual side effects than bupropion,^{3,42,45-50} reboxetine,⁵¹⁻⁵³ and nefazodone.¹¹ Studies comparing mirtazapine with an SSRI demonstrated mixed results, with some studies^{54,55} showing higher rates of sexual dysfunction with SSRIs than with mirtazapine, and other studies⁵⁶⁻⁵⁸ showing no difference between the 2 treatment groups. Of more than 40 randomized, controlled trials that compared SSRIs with venlafaxine, only 1 study³³ employed a measurement of sexual dysfunction. No difference in the prevalence of sexual dysfunction between the 2 treatments was observed in that trial. Studies comparing duloxetine with an SSRI¹⁶⁻¹⁹ suggested no difference in sexual side effect rates between the 2 groups, although recent research^{15,59} suggested that sexual dysfunction is more likely to occur with paroxetine than with duloxetine treatment.

Weight Gain

Patients may experience weight gain during antidepressant treatment. Weight gain in antidepressant trials is most often reported either as a change in weight from baseline or as the proportion of patients who gain more than 7% of their body weight compared to baseline. The results of a large, cross-sectional study (data on file, GlaxoSmithKline, Brentford, Middlesex, U.K.) based on the General Electric Medical Records Database* involv-

ing patients treated for a unipolar depressive episode with antidepressant monotherapy for at least 1 year suggested differences in the proportion of patients who gained 7% or more of their body weight during treatment (Figure 2). Mirtazapine was associated with the highest percentage of patients with weight gain (26%), followed by the SSRIs and venlafaxine (from 16% to 19%).¹⁶ Bupropion and nefazodone demonstrated the lowest rates of weight gain (12%).

Only a subset of all randomized, long-term, controlled studies of antidepressants have reported weight data. Of the newer antidepressants, long-term, randomized, controlled trials confirm that treatment with mirtazapine is associated with significant weight gain. For example, in a double-blind, randomized, placebo-substitution trial⁶⁰ involving the treatment of mirtazapine remitters with major depressive disorder (MDD) treated with either continued mirtazapine or placebo for a total of 40 weeks, mirtazapine-treated patients gained an average of 1.42 kg while patients taking placebo lost an average of 1.67 kg ($p < .001$). However, in a double-blind extension study⁶¹ involving the treatment of MDD with the TCA amitriptyline, mirtazapine, or placebo, amitriptyline was associated with higher rates of weight gain (22%) than mirtazapine (12.7%) or placebo (2.6%).

Several studies suggest that long-term weight change with the SSRIs fluoxetine and escitalopram was similar to that with placebo.⁶²⁻⁶⁵ However, paroxetine was associated with a significantly higher rate of weight gain (25.5%) than sertraline (4.2%; $p = .003$) or fluoxetine (6.8%; $p = .016$).⁶⁶ Reports focusing on duloxetine showed mixed findings, with 1 long-term study⁶⁷ showing no difference in weight change versus placebo following treatment with 60 mg/day of duloxetine, and other long-term studies^{15,68} demonstrating higher rates of 7% or greater

*General Electric Medical Records Database: A database containing patient information from a consortium of 5000 physicians using General Electric Healthcare's CPO Electronic Medical Records, which documents care for about 4 million patients.

weight gain with duloxetine (80 or 120 mg/day) than placebo. However, it is also important to point out that many long-term, placebo-controlled studies of SSRIs⁶⁹⁻⁸⁴ and venlafaxine⁸⁵ report no weight data. This lack of research data makes it difficult to accurately estimate weight change during the long-term treatment of depression with these agents.

Finally, nefazodone, bupropion, and reboxetine appear to result in the lowest rates of weight gain during treatment. Specifically, a pooled analysis⁸⁶ of randomized trials comparing nefazodone with an SSRI reported a 6.9% and 13.8% rate of weight gain, respectively ($p < .01$). Parallel, long-term, double-blind, placebo-controlled studies of bupropion⁸⁷ and reboxetine⁸⁸ have shown no difference in mean weight change compared with placebo.

Other Adverse Events

A number of other adverse events have been reported during antidepressant treatment. For example, studies have hinted at possible effects such as hyperprolactinemia with fluoxetine,⁸⁹ hyponatremia with paroxetine,⁹⁰ and problems with motivation, wakefulness, energy, focus, recall, finding words, and mental acuity with antidepressant treatment in general.⁹¹ Unfortunately, these adverse events have been relatively understudied. Studies have suggested that treatment with the TCAs may result in higher rates of abnormal mood elevations (e.g., mania and hypomania) during the treatment of bipolar depression than the SSRIs paroxetine⁹² and fluoxetine.⁹³ There is a paucity of studies comparing this adverse event among the newer agents. Post et al.⁹⁴ reported lower rates of switching to mania or hypomania among patients with bipolar depression treated with bupropion or sertraline than venlafaxine. Similarly, Vieta et al.⁹⁵ found lower rates of switching to mania or hypomania among paroxetine- than venlafaxine-treated patients with bipolar depression.

Adverse events that rarely occur represent a significant challenge for researchers and clinicians alike. To study rare adverse events, large sample sizes and/or long follow-up times are required. Specifically, during the early 1990s, concerns⁹⁶⁻⁹⁹ were voiced regarding the potential for the SSRIs to worsen suicidal ideation or contribute to the emergence of suicidal ideation early on during the treatment of depression. These concerns were quickly followed by a number of pooled analyses,¹⁰⁰⁻¹⁰² which suggested that SSRIs were no more likely than placebo to worsen suicidal ideation or result in suicide attempts. Recently, concerns resurfaced regarding the potential for antidepressants to contribute to the emergence or worsening of suicidal ideation during the early phases of treatment (first 2 weeks) among children, adolescents, and adults with MDD. This time, concerns were voiced by drug regulatory authorities in the United States and United Kingdom and were followed by several more pooled analyses.¹⁰³⁻¹⁰⁵ These analyses suggest a small increase in

suicidal ideation in the proportion of children and adolescents with MDD during the first few weeks of treatment with the SSRIs. An increased risk in suicide during antidepressant treatment was not demonstrated. Pooled analyses of randomized, controlled trials of antidepressants in adults¹⁰⁶⁻¹¹² found no relationship between an emergence of suicidal ideation, a worsening of suicidal ideation, or an increase in completed suicides during the treatment of MDD compared to placebo. However, a recent study by Thase et al.¹¹³ demonstrated a numerically, but not statistically, higher rate of suicidal behavior among young adults aged 18 to 24 years treated with paroxetine compared with placebo for MDD. Data on venlafaxine, mirtazapine, and sertraline have yet to be published.

Other rare adverse events in need of further research include gastrointestinal bleeding with SSRIs and concomitant administration of nonsteroidal anti-inflammatory drugs¹¹⁴; seizure¹¹⁵ and atopic reactions¹¹⁶ with bupropion; thrombocytopenia, neutropenia, and bone marrow suppression with mirtazapine¹¹⁷⁻¹¹⁹; hepatotoxicity¹²⁰ and priapism¹²¹ with nefazodone; hepatotoxicity,¹²² priapism,¹²³ and cardiac conduction problems¹²⁴ with trazodone; cardiac conduction abnormalities¹²⁵ with venlafaxine; urinary hesitancy/retention and dysuria¹²⁶ with reboxetine; and liver enzyme abnormalities with duloxetine.¹²⁷

CONCLUSION

Antidepressant side effects appear to be common and persistent. They can contribute to discomfort, distress, disability, morbidity, and mortality and can compromise the efficacy of treatments. Reducing the side effect burden, either by developing treatments that have low incidence of side effects or by using treatment strategies that alleviate side effects, would improve the standard of care for mood and anxiety disorders.

Drug names: bupropion (Wellbutrin and others), citalopram (Celexa and others), duloxetine (Cymbalta), escitalopram (Lexapro and others), fluoxetine (Prozac and others), mirtazapine (Remeron and others), paroxetine (Paxil, Pexeva, and others), sertraline (Zoloft and others), venlafaxine (Effexor and others).

Disclosure of off-label usage: The author has determined that, to the best of his knowledge, fluvoxamine, moclobemide, and reboxetine are not approved by the U.S. Food and Drug Administration for the treatment of major depressive disorder.

REFERENCES

1. Hu XH, Bull SA, Hunkeler EM, et al. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. *J Clin Psychiatry* 2004;65:959-965
2. Lin EH, Von Korff M, Lin E, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. *Med Care* 1995;33:67-74
3. Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. *J Clin Psychiatry* 2005;66:974-981
4. Papakostas GI, Fava M. A meta-analysis of clinical trials comparing

- moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. *Can J Psychiatry* 2006;51:783–790
5. Papakostas GI, Homburger CH, Fava M. A meta-analysis of clinical trials comparing mirtazapine with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. *J Psychopharmacol*. In press
 6. Beasley CM Jr, Dornseif BE, Pultz JA, et al. Fluoxetine versus trazodone: efficacy and activating-sedating effects. *J Clin Psychiatry* 1991;52:294–299
 7. Falk WE, Rosenbaum JF, Otto MW, et al. Fluoxetine versus trazodone in depressed geriatric patients. *J Geriatr Psychiatry Neurol* 1989;2:208–214
 8. Munizza C, Olivieri L, Di Loreto G, et al. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder. *Curr Med Res Opin* 2006;22:1703–1713
 9. Kasper S, Olivieri L, Di Loreto G, et al. A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. *Curr Med Res Opin* 2005;21:1139–1146
 10. Baldwin DS, Hawley CJ, Abed RT, et al. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. *J Clin Psychiatry* 1996;57(suppl 2):46–52
 11. Feiger A, Kiev A, Shrivastava RK, et al. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. *J Clin Psychiatry* 1996;57(suppl 2):53–62
 12. Berlanga C, Arechavaleta B, Heinz G, et al. A double-blind comparison of nefazodone and fluoxetine in the treatment of depressed outpatients. *Salud Mental* 1997;20:1–8
 13. Rush AJ, Armitage R, Gillin JC, et al. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. *Biol Psychiatry* 1998;44:3–14
 14. Hicks JA, Argyropoulos SV, Rich AS, et al. Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. *Br J Psychiatry* 2002;180:528–535
 15. Nelson JC, Pritchett YL, Martynov O, et al. The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials. *Prim Care Companion J Clin Psychiatry* 2006;8:212–219
 16. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind, placebo-controlled trial. *J Clin Psychiatry* 2002;63:225–231
 17. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. *Eur Neuropsychopharmacol* 2004;14:457–470
 18. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. *J Clin Psychopharmacol* 2004;24:389–399
 19. Perahia DGS, Wang F, Mallinckrodt CH, et al. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. *Eur Psychiatry* 2006;21:367–378
 20. Greist J, McNamara RK, Mallinckrodt CH, et al. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. *Clin Ther* 2004;29:1446–1455
 21. Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. *J Affect Disord* 1999;56:171–181
 22. Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. *Neuropsychobiology* 2004;50:57–64
 23. Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. *J Clin Psychiatry* 2004;65:1190–1196
 24. Schatzberg A, Roose S. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. *Am J Geriatr Psychiatry* 2006;14:361–370
 25. Nemeroff CB, Thase ME, for the EPIC 014 Study Group. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. *J Psychiatr Res* 2007;41:351–359
 26. DeVane CL. Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. *J Clin Psychiatry* 2003;64(suppl 18):14–19
 27. Dierick M, Ravizza L, Realini R, et al. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpa-
 - tients. *Prog Neuropsychopharmacol Biol Psychiatry* 1996;30:57–71
 28. Tylee A, Beaumont G, Bowden MW, et al. A double-blind, randomized, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice. *Prim Care Psychiatry* 1997;3:51–58
 29. Costa e Silva J. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. *J Clin Psychiatry* 1998;59:352–357
 30. McPartlin GM, Reynolds A, Anderson C, et al. A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice. *Prim Care Psychiatry* 1998;693:127–132
 31. Alves C, Cachola I, Brandao J. Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression. *Prim Care Psychiatry* 1999;5:57–63
 32. Silverstone PH, Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. *J Clin Psychiatry* 1999;60:22–28
 33. Mehtonen OP, Sogaard J, Roponen P, et al. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. *J Clin Psychiatry* 2000;61:95–100
 34. Tzanakaki M, Guazzelli M, Nimatoudis I, et al. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia. *Int Clin Psychopharmacol* 2000;15:29–34
 35. De Nayer A, Geerts S, Ruelens L, et al. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. *Int J Neuropsychopharmacol* 2002;5:115–120
 36. Allard P, Gram L, Timdahl K, et al. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram. *Int J Geriatr Psychiatry* 2004;19:1123–1130
 37. Sir A, D'Souza RF, Uguz S, et al. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. *J Clin Psychiatry* 2005;66:1312–1320
 38. Shelton RC, Haman KL, Rapaport MH, et al. A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder. *J Clin Psychiatry* 2006;67:1674–1681
 39. Ballus C, Quiros G, De Flores T, et al. The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. *Int Clin Psychopharmacol* 2000;15:43–48
 40. Stahl SM, Mendels J, Schwartz GE. Effects of reboxetine on anxiety, agitation, and insomnia: results of a pooled evaluation of randomized clinical trials. *J Clin Psychopharmacol* 2002;22:388–392
 41. Papakostas GI, Nutt DJ, Hallett LA, et al. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. *Biol Psychiatry* 2006;60:1350–1355
 42. Clayton AH, Montejo AL. Major depressive disorder, antidepressants, and sexual dysfunction. *J Clin Psychiatry* 2006;67(suppl 6):33–37
 43. Montejo-Gonzalez AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. *J Sex Marital Ther* 1997;23:176–194
 44. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. *J Clin Psychiatry* 2002;63:357–366
 45. Segraves RT, Kavoussi R, Hughes AR, et al. Evaluation of sexual functioning in depressed outpatients: a double-blind comparison of sustained-release bupropion and sertraline treatment. *J Clin Psychopharmacol* 2000;20:122–128
 46. Coleman CC, Cunningham LL, Foster VJ, et al. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. *Ann Clin Psychiatry* 1999;11:205–215
 47. Kennedy SH, Fulton KA, Bagby RM, et al. Sexual function during bupropion or paroxetine treatment of major depressive disorder. *Can J Psychiatry* 2006;51:234–242
 48. Coleman CC, King BR, Bolden-Watson C, et al. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. *Clin Ther* 2001;23:1040–1058
 49. Weihs KL, Settle EC Jr, Batey SR, et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. *J Clin Psychiatry* 2000;61:196–202
 50. Kavoussi RJ, Segraves RT, Hughes AR, et al. Double-blind comparison of

- bupropion sustained release and sertraline in depressed outpatients. *J Clin Psychiatry* 1997;58:532–537
51. Clayton AH, Zajecka J, Ferguson JM, et al. Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder. *Int Clin Psychopharmacol* 2003;18:151–156
 52. Baldwin D, Bridgman K, Buis C. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. *J Psychopharm* 2006;20:91–96
 53. Langworth S, Bodlund O, Agren H. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder. *J Clin Psychopharmacol* 2006;26:121–127
 54. Benkert O, Szegei A, Kohlen R. Mirtazapine compared with paroxetine in major depression. *J Clin Psychiatry* 2000;61:656–663
 55. Philipp M, Tiller JW, Baier D, et al. Comparison of moclobemide with selective serotonin reuptake inhibitors (SSRIs) on sexual function in depressed adults: the Australian and German Study Groups. *Eur Neuropsychopharmacol* 2000;10:305–314
 56. Behnke K, Sogaard J, Martin S, et al. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. *J Clin Psychopharmacol* 2003;23:358–364
 57. Wade A, Crawford GM, Angus M, et al. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care. *Int Clin Psychopharmacol* 2003;18:133–141
 58. Versiani M, Moreno R, Ramakers-van Moorsel CJ, et al. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. *CNS Drugs* 2005;19:137–146
 59. Delgado PL, Brannan SK, Mallinckrodt CH, et al. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. *J Clin Psychiatry* 2005;66:686–692
 60. Thase ME, Nierenberg AA, Keller MB, et al. Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. *J Clin Psychiatry* 2001;62:782–788
 61. Montgomery SA, Reimitt PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind, placebo-controlled study. *Int Clin Psychopharmacol* 1998;13:63–73
 62. Michelson D, Amsterdam JD, Quitkin FM, et al. Changes in weight during a 1-year trial of fluoxetine. *Am J Psychiatry* 1999;156:1170–1176
 63. Emslie GJ, Heiligenstein JH, Hoog SL, et al. Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study. *J Am Acad Child Adolesc Psychiatry* 2004;43:1397–1405
 64. Gilaberte I, Montejo AL, de la Gandara J, et al. Fluoxetine in the prevention of depressive recurrences: a double-blind study. *J Clin Psychopharmacol* 2001;21:417–424
 65. Kornstein SG, Bose A, Li D, et al. Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial. *J Clin Psychiatry* 2006;67:1767–1775
 66. Fava M, Judge R, Hoog S, et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. *J Clin Psychiatry* 2000;61:863–867
 67. Perahia DG, Gilaberte I, Wang F, et al. Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. *Br J Psychiatry* 2006;188:346–353
 68. Wise TN, Perahia DG, Pangallo BA, et al. Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies. *Prim Care Companion J Clin Psychiatry* 2006;8:269–278
 69. Simon JS, Aquiar LM, Kunz NR, et al. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. *J Psychiatr Res* 2004;38:249–257
 70. Montgomery SA, Entsuah R, Hackett D, et al. Venlafaxine versus placebo in the preventive treatment of recurrent major depression. *J Clin Psychiatry* 2004;65:328–336
 71. Kamijima K, Burt T, Cohen G, et al. A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in Japan. *Int Clin Psychopharmacol* 2006;21:1–9
 72. McGrath PJ, Stewart JW, Quitkin FM, et al. Predictors of relapse in a prospective study of fluoxetine treatment of major depression. *Am J Psychiatry* 2006;163:1542–1548
 73. Lepine JP, Callaïrd V, Bissèrbe JC, et al. A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder. *Am J Psychiatry* 2004;161:836–842
 74. Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. *J Clin Psychiatry* 2004;65:44–49
 75. Klynsner R, Bent-Hansen J, Hansen HL, et al. Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy. *Br J Psychiatry* 2002;181:29–35
 76. Hochstrasser B, Isaksen PM, Koponen H, et al. Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy. *Br J Psychiatry* 2001;178:304–310
 77. Schmidt ME, Fava M, Robinson JM, et al. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. *J Clin Psychiatry* 2000;61:851–857
 78. Keller MB, Kocsis JH, Thase ME, et al. Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. *JAMA* 1998;280:1665–1672
 79. Terra JL, Montgomery SA. Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. *Am J Psychiatry* 1998;155:55–62
 80. Robert P, Montgomery SA. Citalopram in doses of 20–60 mg is effective in depression relapse prevention: a placebo-controlled 6 month study. *Int Clin Psychopharmacol* 1995;10(suppl 1):29–35
 81. Montgomery SA, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. *Int Clin Psychopharmacol* 1993;8:189–195
 82. Montgomery SA, Rasmussen JG, Tanghoj P. A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. *Int Clin Psychopharmacol* 1993;8:181–188
 83. Doogan DP, Caillard V. Sertraline in the prevention of depression. *Br J Psychiatry* 1992;160:217–222
 84. Montgomery SA, Dufour H, Brion S, et al. The prophylactic efficacy of fluoxetine in unipolar depression. *Br J Psychiatry Suppl* 1988;3:69–76
 85. Entsuah AR, Rudolph RL, Hackett D, et al. Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates. *Int Clin Psychopharmacol* 1996;11:137–145
 86. Sussman N, Ginsberg DL, Bikoff J, et al. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials. *J Clin Psychiatry* 2001;62:256–260
 87. Weihs KL, Houser TL, Batey SR, et al. Continuation phase treatment with bupropion SR effectively decreases the risk of relapse for depression. *Biol Psychiatry* 2002;51:753–761
 88. Thase M, Bartlett C. Reboxetine does not cause weight gain during long-term therapy [abstract]. *Eur Neuropsychopharmacol* 2001;11(suppl 3):S215
 89. Papakostas GI, Miller KK, Petersen T, et al. Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. *J Clin Psychiatry* 2006;67:952–957
 90. Fabian TJ, Amico JA, Kroboth PD, et al. Paroxetine-induced hyponatremia in older adults: a 12-week prospective study. *Arch Intern Med* 2004;164:327–332
 91. Fava M, Graves LM, Benazzi F, et al. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. *J Clin Psychiatry* 2006;67:1754–1758
 92. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. *Am J Psychiatry* 2001;158:906–912
 93. Cohn JB, Collins G, Ashbrook E, et al. A comparison of fluoxetine, imipramine, and placebo in patients with bipolar depressive disorder. *Int Clin Psychopharmacol* 1989;4:313–322
 94. Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. *Br J Psychiatry* 2006;189:124–131
 95. Vieta E, Martínez-Arán A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. *J Clin Psychiatry* 2002;63:508–512
 96. Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. *Am J Psychiatry* 1990;147:207–210
 97. Papp LA, Gorman JM. Suicidal preoccupation during fluoxetine treatment. *Am J Psychiatry* 1990;147:1380–1381
 98. Masand P, Gupta S, Dewan M. Suicidal ideation related to fluoxetine treatment. *N Engl J Med* 1991;324:420
 99. Fava M, Rosenbaum JF. Suicidality and fluoxetine: is there a relationship? *J Clin Psychiatry* 1991;52:108–111

100. Beasley CM Jr, Dornseif BE, Bosomworth JC, et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. *BMJ* 1991;303:685-692
101. Montgomery SA, Dunner DL, Dunbar GC. Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. *Eur Neuropsychopharmacol* 1995;5:5-13
102. Letizia C, Kapik B, Flanders WD. Suicidal risk during controlled clinical investigations of fluvoxamine. *J Clin Psychiatry* 1996;57:415-421
103. Whittington CJ, Kendall T, Fonagy P, et al. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. *Lancet* 2004;363:1341-1345
104. Apter A, Lipschitz A, Fong R, et al. Evaluation of suicidal thoughts and behaviors in children and adolescents taking paroxetine. *J Child Adolesc Psychopharmacol* 2006;16:77-90
105. Mosholder AD, Willy M. Suicidal adverse events in pediatric randomized, controlled clinical trials of antidepressant drugs are associated with active drug treatment: a meta-analysis. *J Child Adolesc Psychopharmacol* 2006;16:25-32
106. Pedersen AG. Escitalopram and suicidality in adult depression and anxiety. *Int Clin Psychopharmacol* 2005;20:139-143
107. GlaxoSmithKline Clinical Trial Register. Analysis of data in bupropion clinical trials for suicidality. Available at: http://ctr.gsk.co.uk/Summary/bupropion/IV_suicide_observational.pdf. Accessed March 16, 2007
108. Beasley C, Disch D, Prabhakar V, et al. Potential predictive factors for development of treatment-emergent suicidal ideation in the fluoxetine placebo-controlled major depressive disorder database [poster]. Presented at the 45th annual meeting of the American College of Neuropsychopharmacology (ANCP); Dec 3-7, 2006; Hollywood, Fla
109. Pedersen AG. Citalopram and suicidality in adult major depression and anxiety disorders. *Nord J Psychiatry* 2006;60:392-399
110. Acharya N, Rosen AS, Polzer JP, et al. Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder. *J Clin Psychopharmacol* 2006;26: 587-594
111. Khan A, Khan S, Kolts R, et al. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. *Am J Psychiatry* 2003;160:790-792
112. Hammad TA, Laughren TP, Racoosin JA. Suicide rates in short-term randomized controlled trials of newer antidepressants. *J Clin Psychopharmacol* 2006;26:203-207
113. Thase ME, Carpenter DJ, Fong R, et al. Suicidality in adult paroxetine depression studies [poster]. Presented at the 45th annual meeting of the American College of Neuropsychopharmacology (ANCP); Dec 3-7, 2006; Hollywood, Fla
114. Gupta S, Frank B, Madhusoodanan S. Risperidone-associated galactorrhea in a male teenager [letter]. *J Am Acad Child Adolesc Psychiatry* 2001;40:504-505
115. Dunner DL, Zisook S, Billow AA, et al. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. *J Clin Psychiatry* 1998;59:366-373
116. Loo WJ, Alexandroff A, Flanagan N. Bupropion and generalized acute urticaria: a further case. *Br J Dermatol* 2003;149:440
117. Liu X, Sahud MA. Glycoprotein IIb/IIIa complex is the target in mirtazapine-induced immune thrombocytopenia. *Blood Cells Mol Dis* 2003;30:241-245
118. Kasper S, Praschak-Rieder N, Tauscher J, et al. A risk-benefit assessment of mirtazapine in the treatment of depression. *Drug Saf* 1997;17:251-264
119. Hutchison LC. Mirtazapine and bone marrow suppression: a case report. *J Am Geriatr Soc* 2001;49:1129-1130
120. Carvajal Garcia-Pando A, Garcia del Pozo J, Sanchez AS, et al. Hepatotoxicity associated with the new antidepressants. *J Clin Psychiatry* 2002;63:135-137
121. Toofanny N, Maddens ME. Reversible penile priapism associated with nefazodone. *J Am Geriatr Soc* 2002;50:1610-1611
122. Fernandes NF, Martin RR, Schenker S. Trazodone-induced hepatotoxicity: a case report with comments on drug-induced hepatotoxicity. *Am J Gastroenterol* 2000;95:532-535
123. Bardin ED, Krieger JN. Pharmacological priapism: comparison of trazodone- and papaverine-associated cases. *Int Urol Nephrol* 1990;22:147-152
124. Irwin M, Spar JE. Reversible cardiac conduction abnormality associated with trazodone administration. *Am J Psychiatry* 1983;140:945-946
125. Combes A, Peytavin G, Theron D. Conduction disturbances associated with venlafaxine. *Ann Intern Med* 2001;134:166-167
126. Kasper S, Wolf R. Successful treatment of reboxetine-induced urinary hesitancy with tamsulosin. *Eur Neuropsychopharmacol* 2002;12:119-122
127. Hanje AJ, Pell LJ, Votolato NA, et al. Case report: fulminant hepatic failure involving duloxetine hydrochloride. *Clin Gastroenterol Hepatol* 2006;4:912-917